Stay updated on Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1; the page remains a 403 error.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now shows a 403 Forbidden error page, replacing the previously visible study record details for the trial and offering a Home link instead.SummaryDifference18%

- Check22 days agoChange DetectedThe page now shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates an updated version of the study page document.SummaryDifference0.0%

- Check36 days agoChange DetectedThe page shows Revision: v3.6.6 replacing v3.6.5, indicating a new build of the page. This appears to be a software update rather than a change to study information.SummaryDifference0.0%

- Check43 days agoChange DetectedAn NIH grant/contract entry for 2018 was added to the study's identifiers section. This clarifies the funding source associated with the trial and enhances transparency of sponsorship.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page now displays Revision: v3.6.5 in place of v3.6.4, indicating a version update for the page. This appears to be a maintenance update rather than a change to study content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.